Endocrine Abstracts

The primary treatment for prostate cancer (PCa) involves androgen ablation, halting tumour growth through down-regulation of androgen-regulated proliferative genes1. Frequently PCa progresses to an androgen-independent state and untreatable disease. The Androgen receptor (AR) continues to be expressed in many of these tumours, often associated with androgen-independent activation of the AR signalling pathway. Thus, the aim of the study is to understand regulation of...